Total Funding
77
1
Total FundingConvertible Note raised
Growth Score
-7 pts
Heat Score
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
678113
Kalos Therapeutics develops atrial natriuretic peptides for the treatment of cancer.
James Merritt: President and CMO of Kalos Therapeutics
George Colberg: Executive Chairman, CEO, and Co-Founder
About the Company
Kalos Therapeutics is an emerging biomedical company with the exclusive patent to develop the ANP (atrial natriuretic peptide) family of peptides as a new mechanism for the treatment of cancer. Kalos is aggressively targeting diseases caused by an abnormally high growth rate of cells (hyperproliferation). Kalos is pioneering an approach to cancer
treatment by developing peptides made primarily in the heart as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small-molecule compounds.
